Vasomotor Symptoms Market Poised for Growth, Driven by New Therapies

The market for vasomotor symptoms (VMS) treatment is projected to experience substantial growth through 2036. This expansion is attributed to improved diagnosis, advancements in treatment options, an aging demographic, and increased awareness of menopausal symptoms.

Growth is further supported by the anticipated launch of emerging therapies such as Cendifensine, Asimadoline, and ABCL635. Increased healthcare spending across key markets, including the United States, Europe, and Japan, is also expected to contribute to the market's positive trajectory.

The United States represented the largest market for VMS treatments in 2025. The prevalence of vasomotor symptoms is estimated at approximately 46% during the early menopausal transition, rising to 60-80% during and after menopause.

Several companies, including Noema Pharma and Tioga Pharmaceuticals, are developing new treatments. Promising candidates in clinical trials include Refisolone and MNGX-100. Growing awareness of menopause management and a rising demand for safe, non-hormonal alternatives are fueling the market's advancement.